Effective long‐term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER / ENABLE
Pediatric Allergy and Immunology · 2025
DOI: 10.1111/pai.70072 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Pediatric Allergy and Immunology, 2025. Verfasst von Raffi Tachdjian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology and Rheumatology, UCLA School of Medicine, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc.
Abstract (Originalsprache)
Background
Symptoms of hereditary angioedema (HAE) typically first present during childhood, but the frequency/severity of attacks often increases at puberty. Real‐world data on long‐term HAE prophylaxis in adolescents are limited. We report pooled data from adolescent patients enrolled in two Phase 4 studies (EMPOWER, ENABLE) evaluating the effectiveness/safety of lanadelumab (monoclonal antibody directed against plasma kallikrein) for the prevention of HAE attacks.
Methods
Adolescent patients (aged 12 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Immunology and Rheumatology, UCLA School of Medicine, Los Angeles, California, USA.
- Providence St. John Medical Center, Santa Monica, California, USA.
- Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Allergy and Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Clinical Immunology, Angioedema and Allergy Institute, The Center for Autoimmune Diseases, Sheba Medical Center, Tel HaShomer Hospital, Ramat-Gan, Israel.
- AllerVie Health, Birmingham, Alabama, USA.
ORCID-Profile: Mauro Cancian
Förderung
- Takeda Development Center Americas, Inc
Zitieren
APA
Tachdjian, R., Banerji, A., Busse, P. J., Agmon-Levin, N., Anderson, J., Cancian, M., Spadaro, G., Enciu, C., Estepan, D. N., Khutoryansky, N., Jain, S., & Recke, A. (2025). Effective long‐term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER / ENABLE. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70072
Vancouver
Tachdjian R, Banerji A, Busse PJ, Agmon-Levin N, Anderson J, Cancian M, et al. Effective long‐term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER / ENABLE. Pediatric Allergy and Immunology. 2025. doi:10.1111/pai.70072
BibTeX
@article{Tachdjian2025,
author = {Tachdjian, Raffi and Banerji, Aleena and Busse, Paula J and Agmon-Levin, Nancy and Anderson, John and Cancian, Mauro and Spadaro, Giuseppe and Enciu, Carmen and Estepan, Daniel Nova and Khutoryansky, Natalie and Jain, Siddharth and Recke, Andreas},
title = {Effective long‐term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER / ENABLE},
journal = {Pediatric Allergy and Immunology},
year = {2025},
doi = {10.1111/pai.70072}
}
EUVIMED